Literature DB >> 18704954

Vaccine adjuvants: current challenges and future approaches.

Jennifer H Wilson-Welder1, Maria P Torres, Matt J Kipper, Surya K Mallapragada, Michael J Wannemuehler, Balaji Narasimhan.   

Abstract

For humans, companion animals, and food producing animals, vaccination has been touted as the most successful medical intervention for the prevention of disease in the twentieth century. However, vaccination is not without problems. With the development of new and less reactogenic vaccine antigens, which take advantage of molecular recombinant technologies, also comes the need for more effective adjuvants that will facilitate the induction of adaptive immune responses. Furthermore, current vaccine adjuvants are successful at generating humoral or antibody mediated protection but many diseases currently plaguing humans and animals, such as tuberculosis and malaria, require cell mediated immunity for adequate protection. A comprehensive discussion is presented of current vaccine adjuvants, their effects on the induction of immune responses, and vaccine adjuvants that have shown promise in recent literature.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18704954      PMCID: PMC8092333          DOI: 10.1002/jps.21523

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  217 in total

1.  CD28, Ox-40, LFA-1, and CD4 modulation of Th1/Th2 differentiation is directly dependent on the dose of antigen.

Authors:  P R Rogers; M Croft
Journal:  J Immunol       Date:  2000-03-15       Impact factor: 5.422

2.  Vaccine delivery to animals.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1999-07-26       Impact factor: 15.470

Review 3.  Single-administration vaccines: controlled-release technology to mimic repeated immunizations.

Authors:  J L Cleland
Journal:  Trends Biotechnol       Date:  1999-01       Impact factor: 19.536

4.  Cytokines: making the right choice.

Authors:  F D Finkelman; J F Urban
Journal:  Parasitol Today       Date:  1992-09

5.  Use of an oral diphtheria vaccine in human.

Authors:  Niclas Rydell; Linda Stertman; Gunnemar Stålenheim; Ingvar Sjöholm
Journal:  Vaccine       Date:  2006-03-29       Impact factor: 3.641

Review 6.  Veterinary vaccines for animal and public health.

Authors:  P P Pastoret; P Jones
Journal:  Dev Biol (Basel)       Date:  2004

Review 7.  (How) do aluminium adjuvants work?

Authors:  James M Brewer
Journal:  Immunol Lett       Date:  2005-08-30       Impact factor: 3.685

8.  Self-assembled quantum dot-peptide bioconjugates for selective intracellular delivery.

Authors:  James B Delehanty; Igor L Medintz; Thomas Pons; Florence M Brunel; Philip E Dawson; Hedi Mattoussi
Journal:  Bioconjug Chem       Date:  2006 Jul-Aug       Impact factor: 4.774

9.  Protective vaccination against murine visceral leishmaniasis using aldehyde-containing Quillaja saponaria sapogenins.

Authors:  C B Palatnik de Sousa; W R Santos; C P Casas; E Paraguai de Souza; L W Tinoco; B P da Silva; M Palatnik; J P Parente
Journal:  Vaccine       Date:  2004-06-23       Impact factor: 3.641

10.  Ovalbumin peptide encapsulated in poly(d,l lactic-co-glycolic acid) microspheres is capable of inducing a T helper type 1 immune response.

Authors:  K D Newman; J Samuel; G Kwon
Journal:  J Control Release       Date:  1998-06       Impact factor: 9.776

View more
  76 in total

1.  Collagen type II and a thermo-responsive polymer of N-isopropylacrylamide induce arthritis independent of Toll-like receptors: a strong influence by major histocompatibility complex class II and Ncf1 genes.

Authors:  Akhilesh Kumar Shakya; Ashok Kumar; Dorota Klaczkowska; Malin Hultqvist; Kristin Hagenow; Rikard Holmdahl; Kutty Selva Nandakumar
Journal:  Am J Pathol       Date:  2011-09-18       Impact factor: 4.307

Review 2.  Safety and tolerability evaluation of the use of Montanide ISA™51 as vaccine adjuvant: A systematic review.

Authors:  Eva van Doorn; Heng Liu; Anke Huckriede; Eelko Hak
Journal:  Hum Vaccin Immunother       Date:  2015-09-17       Impact factor: 3.452

Review 3.  Role of adjuvants in modeling the immune response.

Authors:  Darrick Carter; Steven G Reed
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

Review 4.  Chitosan: a promising safe and immune-enhancing adjuvant for intranasal vaccines.

Authors:  Alan Smith; Michael Perelman; Michael Hinchcliffe
Journal:  Hum Vaccin Immunother       Date:  2013-12-17       Impact factor: 3.452

Review 5.  Development of vaccines to treat opioid use disorders and reduce incidence of overdose.

Authors:  Marco Pravetoni; Sandra D Comer
Journal:  Neuropharmacology       Date:  2019-06-04       Impact factor: 5.250

6.  A TLR2 agonist is a more effective adjuvant for a Chlamydia major outer membrane protein vaccine than ligands to other TLR and NOD receptors.

Authors:  Chunmei Cheng; Pooja Jain; Ilham Bettahi; Sukumar Pal; Delia Tifrea; Luis M de la Maza
Journal:  Vaccine       Date:  2011-07-08       Impact factor: 3.641

7.  Self-encapsulating Poly(lactic-co-glycolic acid) (PLGA) Microspheres for Intranasal Vaccine Delivery.

Authors:  Brittany A Bailey; Kashappa-Goud H Desai; Lukasz J Ochyl; Susan M Ciotti; James J Moon; Steven P Schwendeman
Journal:  Mol Pharm       Date:  2017-08-22       Impact factor: 4.939

Review 8.  Current state and challenges in developing oral vaccines.

Authors:  Julia E Vela Ramirez; Lindsey A Sharpe; Nicholas A Peppas
Journal:  Adv Drug Deliv Rev       Date:  2017-04-22       Impact factor: 15.470

9.  Polymer chemistry influences monocytic uptake of polyanhydride nanospheres.

Authors:  Bret D Ulery; Yashdeep Phanse; Avanti Sinha; Michael J Wannemuehler; Balaji Narasimhan; Bryan H Bellaire
Journal:  Pharm Res       Date:  2008-11-06       Impact factor: 4.200

10.  Microneedle-based transcutaneous immunisation in mice with N-trimethyl chitosan adjuvanted diphtheria toxoid formulations.

Authors:  Suzanne M Bal; Zhi Ding; Gideon F A Kersten; Wim Jiskoot; Joke A Bouwstra
Journal:  Pharm Res       Date:  2010-06-18       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.